The Hydration Pharmaceuticals Company Limited confirm it has secured key regulatory approval for product manufacturing for the Canadian market. The Company advises that it has formally received manufacturing approval from Health Canada - a key regulatory update which allows Hydralyte North America's US-based contract manufacturer to commence production of the Company's liquid range for the Canadian market. The Health Canada approval was viewed by the management team as a strategic priority which allows the Company to optimise its manufacturing processes from a centralised production hub, and capitalise on its existing distribution channels across the North American market.

Hydralyte North America currently sells four stock keeping units (SKU) under its ready-to-drink range which are stocked by major Canadian retail outlets, including Shoppers Drug Mart and a large number of independent stores. Securing Health Canada approval for manufacturing in the US is expected to lead to a reduction in cost of goods sold, cheaper freights and potentially underpin an increase in gross margins for the Company's liquid SKUs.